




RealRate

PHARMACEUTICAL 2021

ImmunoGen Inc.
Rank 133 of 409

immunogen



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 179% points. The greatest weakness of ImmunoGen Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is -26%, being 328% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	324,254
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	122,323
Liabilities, Non-Current	102,097
Other Assets	25,058
Other Compr. Net Income	0
Other Expenses	24,689
Other Liabilities	41,082
Other Net Income	1,210
Property and Equipment	5,760
Research and Development	114,592
Revenues	132,299
Selling, General and Administrative Expense	38,600

Output Variable	Value in 1000 USD
Assets	355,072
Liabilities	265,502
Expenses	177,881
Stockholders Equity	89,570
Net Income	-44,372
Comprehensive Net Income	-44,372
Economic Capital Ratio	-26%